Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

79.80CHF
22 Sep 2017
Change (% chg)

CHF-0.15 (-0.19%)
Prev Close
CHF79.95
Open
CHF79.80
Day's High
CHF81.50
Day's Low
CHF79.65
Volume
233,874
Avg. Vol
65,294
52-wk High
CHF95.35
52-wk Low
CHF66.00

Summary

Name Age Since Current Position

Domenico Scala

52 2016 Chairman of the Board of Directors

Ronald Scott

62 2013 Chief Executive Officer, Member of the Management Committee

Thomas Rinderknecht

63 2016 Vice Chairman of the Board of Directors

Donato Spota

2013 Member of the Management Committee, Chief Financial Officer

Guenter Ditzinger

2016 Chief Technology Officer, Member of the Management Committee

Laurenz Kellenberger

2009 Member of the Management Committee, Chief Scientific Officer

David Veitch

50 2014 Chief Commercial Officer, Member of the Management Committee

Achim Kaufhold

2010 Member of the Management Committee, Chief Medical Officer

Daniel Lew

69 2003 Member of the Board of Directors

Alf Nicklasson

62 2016 Member of the Board of Directors

Nicole Onetto

64 2017 Member of the Board of Directors

Steven Skolsky

61 2011 Member of the Board of Directors

Thomas Werner

61 2011 Member of the Board of Directors

Peer Schroeder

2016 Head of Corporate Communications & Investor Relations

Biographies

Name Description

Domenico Scala

Mr. Domenico Scala has been Chairman of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. He is Chairman of the Audit Committee at the Company. Prior to that, he was Vice Chairman of the Board of Directors at the Company from April 9, 2013. Previously, he was Member of the Board of Directors at the Company from April 6, 2011. From 2007 to 2011, Mr. Scala was President and Chief Executive Officer of Nobel Biocare Holding AG and from 2003 to 2007, he was Chief Financial Officer of Syngenta International AG. From 1995 to 2003, he served in various senior leadership positions at Roche Holding AG. Prior to that, he served as Finance Director with Panalpina Italy Spa and Senior Auditor with Nestle SA. Mr. Scala was elected as a Member of the Bank Council of the Basler Kantonalbank in December 2016 (term starting on April 1, 2017). In addition, Mr. Scala has been President of BaselArea, Chairman of the Board of Directors of BAK Basel Economics AG and a Member of the Board of Overseers of Tufts University in Boston, Massachusetts. From May 2012 until May 2016, Mr. Scala was Chairman of the Audit and Compliance Committee of FIFA (Federation Internationale de Football Association). Mr. Scala graduated from the University of Basel with a degree in economics and holds Executive Development degrees from INSEAD and London Business School.

Ronald Scott

Mr. Ronald Scott has been Chief Executive Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd since January 1, 2013. He was Basilea’s COO from January 2012 through December 2012, and served as Basilea’s CFO from the Company’s founding in 2000 through January 2012 as well as ad interim CFO from February 7, 2013 until November 4, 2013. Prior to joining the Company, he worked for nine years at Roche in management positions in Pharmaceutical Finance, Licensing and the Roche Corporate Finance Mergers and Acquisitions group. His assignments included managing Roche's call, primary and secondary offerings on Genetech, Roche's biotechnology investment portfolio, acquisitions and divestitures. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation as Director in Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a Bachelor’s degree from Utah State University and a Master’s degree from Harvard University.

Thomas Rinderknecht

Dr. Thomas M. Rinderknecht has been Vice Chairman of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. He was Member of the Board of Directors of the Company from April 6, 2011. He is Chairman of the Corporate Governance Committee and Member of the Audit Committee at the Company. Dr. Rinderknecht is a senior partner at the law firm Badertscher Rechtsanwaelte AG, in Zurich and Zug. He currently serves as Member of the Board and the Audit Committee of Chocoladefabriken Lindt & Spruengli AG (starting April 2016); as Chairman of the Canyon Pharmaceuticals Group of Companies, Spanset Inter AG, Wollerau, and Caveat Holding AG, Hergiswil; as Vice Chairman of APR Applied Pharma Research SA, Balerna, and the Marquard Media Group. He also serves as Member of the Board of InSphero AG, Schlieren; Twin Dolphins AG, Zug, ADC Therapeutics SA, Epalinges (starting May 2016); Hotel de la Paix SA, Geneva (starting April 2016); the jointly controlled Badertscher Rechtsanwaelte AG and Veritas Trust AG/Fundmaster AG Family Office Companies; and the NorseSatCom/iJet Group of Companies. Until February 2016 he served as Chairman of Vecap Venture Capital Partners AG, Stansstad, and of FLH Brands AG, Zug. Dr. Rinderknecht holds a Ph.D. degree in law from Universitaet Zuerich and is admitted to the Bar in Zurich.

Donato Spota

Mr. Donato Spota has been Member of the Management Committee and Chief Financial Officer of Basilea Pharmaceutica Ltd since November 2013. Mr. Spota has held various positions at Basilea since joining the company in 2002, including Global Head of Finance & Services and Head of Global Controlling. Prior to joining Basilea, Mr. Spota held positions in financial planning and controlling at F. Hoffmann-La Roche, Basel, in the area of Pharma Global Informatics. Mr. Spota has a degree in Information Technology from the Swiss BBT (Bundesamt fuer Berufsbildung und Technologie) and holds a Master degree in business administration from the University of Applied Sciences Nuertingen (Germany).

Guenter Ditzinger

Dr. Guenter Ditzinger has been Chief Technology Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd since February 1, 2016. He joined Basilea in 2002 as CMC Project Leader & Pharmaceutical Development Manager. He was promoted in 2009 to Head of Pharmaceutics in which position he led the pharmaceutical development and manufacturing group and acted as deputy Chief Technology Officer. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland. Dr. Ditzinger holds a Ph.D. in Pharmaceutical Technology from Johann Wolfgang Goethe-Universitaet Frankfurt am Main.

Laurenz Kellenberger

Dr. Laurenz Kellenberger, Ph.D., has been Member of the Management Committee and Chief Scientific Officer of Basilea Pharmaceutica Ltd since January 27, 2009. He holds a Doctorate in Philosophy degree in Organic Chemistry from Swiss Federal Institute of Technology (ETH Zuerich). He continued his scientific research at University of Cambridge and at Hoffmann-La Roche, where he held different positions in preclinical research and chemical technologies before joining the Company in 2000. He is author of a number of scientific publications. At the Company, he held various roles of increasing responsibility and served as Head of Chemistry and Member of the Research Management Team with responsibilities for key projects from lead finding and optimization through to preclinical development. He is Member of the Board of the Medicinal Chemistry & Chemical Biology division of the Swiss Chemical Society.

David Veitch

Mr. David Veitch has been Chief Commercial Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd since September 1, 2014. Mr. Veitch served as the President of European Operations at Savient Pharmaceuticals from 2012 to 2013. From 2007 to 2011, he served as Senior Vice President of European Marketing & Brand Commercialization at Bristol-Myers Squibb Pharmaceuticals. From 2004 to 2007, he was Vice President and General Manager UK at Bristol- Myers Squibb Pharmaceuticals. Prior to this Mr. Veitch held various general management and commercial roles in Bristol-Myers Squibb Pharmaceuticals and prior to that with SmithKline Beecham Pharmaceuticals. Mr. Veitch received a B.Sc. in Biology from the University of Bristol.

Achim Kaufhold

Prof. Achim Kaufhold, M.D., has served as Member of the Management Committee and Chief Medical Officer of Basilea Pharmaceutica Ltd since February 1, 2010. He holds a medical degree from Universitaet zu Koeln. He worked in the fields of pediatrics, basic and applied medical microbiology, laboratory medicine and infectious diseases in Germany and the United States. He is Professor of Medical Microbiology and Infectious Diseases and Member of the Faculty of Medicine of the University of Aachen. Prof. Kaufhold has spent more than 17 years in senior management positions in the biotechnology and pharmaceutical industry, mainly in leadership roles in research, product and business development, and general management. Prior to joining the Company, he was President & Chief Executive Officer of Affitech A/S, previously Pharmexa A/S. His previous senior management roles included Chief Medical Officer & Vice President of Development, Member of the Executive Committee at Chiron, now part of the Novartis group. He was also Chief Medical Officer, Head of Research, Product & Business Development, Member of the Executive Committee at Berna Biotech, now a Crucell company. He was also Director Clinical Development & Head of the Pediatric Vaccines Development Unit at GlaxoSmithKline Biologicals with global responsibility for the development of that company's pediatric vaccine portfolio.

Daniel Lew

Prof. Daniel Lew has been Member of the Board of Directors at Basilea Pharmaceutica Ltd. since 2003. He is Member of the Corporate Governance Committee at the Company. Since 1981, Prof. Lew has been a clinical infectious diseases physician. Prof. Lew is also an Honorary Professor of Medicine at the University of Geneva Medical School, president of the Swiss Academic Foundation for Education in Infectious Diseases (SAFE-ID) and Member of the Swiss Academy of Medical Sciences. Since 1981, he has held various positions at the Geneva University Hospital, including Chief of the Service of Infectious Diseases and the Academic Department of Internal Medicine. From 2010 to 2012, Prof. Lew was President of the International Society for Infectious Diseases (ISID). He received his M.D. from Geneva University and specialized in infectious diseases both in Geneva and then subsequently at Harvard Medical School and Massachusetts General Hospital.

Alf Nicklasson

Dr. Martin Nicklasson, Ph.D., has been Member of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. Prior to that, he was Chairman of the Board of Directors of the Company from 2013. He is Chairman of the Compensation Committee and Member of the Audit Committee and the Corporate Governance Committee at the Company. He is an honorary Associate Professor at the Pharmaceutical Faculty, University of Uppsala (Sweden) since 1985. He is currently a senior partner at Nicklasson Life Science AB. From 2007 to 2010, Dr. Nicklasson served as President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc., and acted as a Member of the Executive Committee. Dr. Nicklasson is Member of the Board of Biocrine AB (Sweden), BioInvent International AB (Sweden), PledPharma AB (Sweden) and Chairman of the Board of Directors of Farma Investment AS (Norway), Orexo AB (Sweden) and Zealand Pharma A/S (Denmark). Dr. Nicklasson is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the University of Uppsala.

Nicole Onetto

Dr. Nicole Onetto is Member of the Board of Directors of Basilea Pharmaceutica Ltd since April 2017. She is currently an independent consultant in oncology, drug development and translational research. Previously, from 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada. From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc. Between 2002 and 2005, she served at OSI Pharmaceuticals, Inc., first as Executive Vice President-Oncology, and then as Chief Medical Officer and Executive Vice President. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc. She is currently on the board of ProNAi Therapeutics, a Vancouver-based oncology hematology company, and previously served for eleven years as a member of the board of ImmunoGen Inc. and of the boards of a number of other public and private pharmaceutical companies in the oncology sector.

Steven Skolsky

Mr. Steven D. Skolsky has been Member of the Board of Directors at Basilea Pharmaceutica Ltd. since April 6, 2011. Prior to that, he served as Vice Chairman of the Board of Directors of the Company from April 29, 2009. He has served as Member of the Board of Directors from March 19, 2008 until April 29, 2009. He is Member of the Compensation Committee at the Company. From 2011 until August 2016, Mr. Skolsky served as a Senior Executive at Quintiles Transnational Holdings in various positions, most recently as Senior Vice President and Managing Director and previously, Head of Global Clinical Operations. From 2006 to 2011, Mr. Skolsky served as Chief Executive Officer and President of Sequoia Pharmaceuticals Inc. and from 2004 to 2006 as Chief Executive Officer of Trimeris Inc. Mr. Skolsky joined Trimeris from GlaxoSmithKline (GSK), where he had served for more than 20 years in a range of senior leadership roles, including Senior Vice President, Global Product Strategy and Clinical Development, and Managing Director of GSK’s operations in Australia and New Zealand. Mr. Skolsky serves on the Foundation Board of the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill (USA). Mr. Skolsky holds a B.A. in Biology from the University of North Carolina at Chapel Hill.

Thomas Werner

Dr. Thomas Werner has been Member of the Board of Directors at Basilea Pharmaceutica Ltd since November 29, 2011. He is Member of the Compensation Committee at the Company. Dr. Werner served as Senior Vice President and Managing Director of GlaxoSmithKline Germany from 2001 to 2008. From 1997 to 2000, he served as Managing Director for Glaxo Wellcome Germany and Director of the Central European Region. Dr. Werner has also worked at Bristol- Myers Squibb Germany and Convatec Germany/ Central Europe. Dr. Werner is Member of the Boards of Vectura Group plc and BSN Medical GmbH and is Member of the Advisory Board of Riemser Pharma GmbH. He also serves as the Chairman of the investment advisory committee of the Health for Life Capital fund of Seventure Partners (France). He holds a Ph.D. in Chemistry from Georg-August-Universitaet Goettingen.

Peer Schroeder